Europe Liquid Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments, Consumables Kits and Reagents, and  Software and Services), By Biomarker (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vehicles (EVs), and Others), By Technology (Multi-gene parallel Analysis (NGS) and Single Gene Analysis (PCR Microarrays)), By Clinical Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, and Others), By Application (Cancer and Reproductive Health), By End-Use (Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others), and Europe Liquid Biopsy Market Insights, Industry Trend, Forecasts to 2035

Europe Liquid Biopsy Market Insights Forecasts to 2035

• The Europe Liquid Biopsy Market Size was estimated at USD 1.05 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 18.03% from 2025 to 2035
• The Europe Liquid Biopsy Market Size is Expected to Reach USD 6.50 Billion by 2035

 

According to a research report published by Spherical Insights & Consulting, the Europe Liquid Biopsy Market Size is Anticipated to Reach USD 6.50 Billion by 2035, Growing at a CAGR of 18.03% from 2025 to 2035. The growing prevalence of cancer, need for non invasive diagnostic tools, and technological advancements in genomics are driving the liquid biopsy market in the Europe region.

 

Market Overview

The Europe liquid biopsy market is the industry associated with the development, manufacturing, and commercialization of non invasive medical tests that analyze biomarkers in bodily fluids, primarily blood, to detect, monitor, and manage diseases, particularly cancer, at an early stage. Liquid biopsy is a minimally invasive method aimed at detecting circulating tumor derived components in body fluids, providing an alternative to current cancer screening methods. This laboratory test enables multiple samples to be taken over time, which may aid in understanding the kind of genetic or molecular changes that take place in the tumor. Technological advancements in liquid biopsy tests, including next generation sequencing (NGS) and improved biomarker detection methods, are enhancing the sensitivity and reliability of the tests. Furthermore, AI integration into liquid biopsy aids in enhancing the diagnostic accuracy by analyzing the extensive data from blood and non-solid samples. Increasing emphasis on precision medicine is driving the use of liquid biopsies to detect, monitor, and guide personalized cancer treatment in real time. The increasing importance of companion diagnostics with the use of next-generation sequencing technology is providing an opportunity in the liquid biopsy market.

 

Report Coverage

This research report categorizes the market for the Europe liquid biopsy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe liquid biopsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe liquid biopsy market.

 

Driving Factors

The increasing prevalence of cancer cases is responsible for driving the demand for liquid biopsy as it is considered the gold standard for tumor diagnosis with a high level of laboratory standardization, good consistency of results, and relatively stable samples. It was estimated that Cancer is the second leading cause of death in Europe, with 1.1 million deaths, which is 21.6% of the total number of deaths in region. Biotechnological advancements drive the development of minimally invasive approaches for diagnosis, ultimately propelling the growth of the liquid biopsy market. Furthermore, technological advancements in liquid biopsy, including next-generation sequencing for precise genomic analysis of biomarkers, significantly contribute to market growth.

 

Restraining Factors

The high costs of liquid biopsy that lead to affordability issues, as well as inconsistent approval pathways and unclear reimbursement policies, are challenging the market. Further, the lack of awareness and clinical utility of this test limits its adoption, thereby restraining the market growth.

 

Market Segmentation

The Europe liquid biopsy market share is classified into product, biomarker, technology, clinical application, application, and end-use.

 

• The consumables kits and reagents segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Europe liquid biopsy market is segmented by material product into instruments, consumables kits and reagents, and software and services. Among these, the consumables kits and reagents segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment includes extraction kits, library preparation, purification kits, and control materials. Introduction of advanced diagnostic assay kits for faster and reliable results is propelling the market growth in the consumable kits and reagents segment.

 

• The circulating tumor DNA (ctDNA) segment held a significant share in 2024 and is expected to grow at the fastest CAGR during the forecast period.

The Europe liquid biopsy market is segmented by biomarker into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vehicles (EVs), and others. Among these, the circulating tumor DNA (ctDNA) segment held a significant share in 2024 and is expected to grow at the fastest CAGR during the forecast period. ctDNA is a preferable biomarker used in precision oncology, companion diagnostics, and research applications, providing real-time insights into tumor genetics. An increasing demand for cancer diagnostics, along with improved government funding, aids in driving the market.

 

• The multi-gene parallel analysis (NGS) accounted for a major share of the liquid biopsy market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The Europe liquid biopsy market is segmented by technology into multi-gene parallel analysis (NGS) and single gene analysis (PCR Microarrays). Among these, the multi-gene parallel analysis (NGS) accounted for a major share of the liquid biopsy market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. NGS provides detailed observation of multiple genetic mutations for a single test, ideal for comprehensive cancer profiling. The growth of precision medicine and the declining cost of sequencing are driving its adoption, thereby propelling the market growth.

 

• The therapy selection segment dominated the liquid biopsy market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

The Europe liquid biopsy market is segmented by clinical application into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring, and others. Among these, the therapy selection segment dominated the liquid biopsy market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Liquid biopsy identifies specific genetic mutations, detects treatment resistance, and monitors patient response to therapy in real time. It ultimately helps in making clinical decisions for healthcare professionals, with improved patient outcomes.  

 

• The cancer segment held the largest market share in 2024 and is projected to grow at a significant CAGR during the forecast period.

The Europe liquid biopsy market is segmented by application into cancer and reproductive health. Among these, the cancer segment held the largest market share in 2024 and is projected to grow at a significant CAGR during the forecast period. Liquid biopsy is used for detecting cancer-related materials such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from bodily fluids. The increasing popularity of minimally invasive cancer diagnostics, along with increasing R&D for numerous novel and emerging biomarkers in cancer, is driving the market.

 

• The hospitals and laboratories segment dominated the market in 2024 and is expected to grow at a significant CAGR during the projected timeframe.

The Europe liquid biopsy market is segmented by end-use into hospitals and laboratories, specialty clinics, academic and research centers, and others. Among these, the hospitals and laboratories segment dominated the market in 2024 and is expected to grow at a significant CAGR during the projected timeframe. This is attributed to the presence of strong healthcare infrastructure, specialized equipment, and trained professionals. Liquid biopsy tests are performed in hospitals and laboratories to aid in guiding and monitoring treatment response.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe liquid biopsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Roche
• Guardant Health
• Sysmex Inostics
• Biocartis
• Agena Bioscience
• Angle plc (UK)
• Inivata
• Diaceutics
• Oncology Venture
• NeoGenomics Laboratories
• Eli Lilly
• AstraZeneca
• Pfizer
• Janssen
• Novartis
• Merck KGaA
• Bayer
• Ipsen
• BeiGene
• Others

 

Recent Developments:

• In June 2025, SeqOne and Agilent announced a strategic collaboration to advance liquid biopsy data analysis for oncology applications. This partnership would deliver two powerful, integrated solutions, SomaMethyl and SomaLBx, optimized for Agilent's cutting-edge Avida Cancer panels and integrated into SeqOne's advanced bioinformatics platform.

 

• In April 2025, Precision for Medicine, a leading provider of drug development and commercialization services, announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and precision medicine services.

 

• In February 2025, Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease detection technology, announced an expanded strategic collaboration with Allogene Therapeutics, Inc. to include the development of the Company's minimal residual disease (MRD) assay as a companion diagnostic.

 

• In February 2025, Dxcover Limited, a clinical-stage diagnostics company pioneering its multiomic spectral analysis (MOSA-Dx) for early detection of solid tumor cancers, announced its next key stage of growth with the closing of significant funding to drive innovation and expand its commercial presence.

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Europe Liquid Biopsy Market based on the below-mentioned segments:

 

Europe Liquid Biopsy Market, By Product

• Instruments
• Consumables Kits and Reagents
• Software and Services

 

Europe Liquid Biopsy Market, By Biomarker

• Circulating Tumor Cells (CTCs)
• Circulating Tumor DNA (ctDNA)
• Extracellular Vehicles (EVs)
• Others

 

Europe Liquid Biopsy Market, By Technology

• Multi-gene parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

 

Europe Liquid Biopsy Market, By Clinical Application

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others

 

Europe Liquid Biopsy Market, By Application

• Cancer
• Reproductive Health

 

Europe Liquid Biopsy Market, By End-Use

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others